# US 2020/0270273 A1 · Heterocyclic amides as kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0270273 A1
- Document ID: US20200270273A1
- Status: Published application
- Kind: A1
- Application number: 16/061,497
- Filed: 2016-12-21
- Published: 2020-08-27
- Earliest claimed: 2015-12-21
- Assignees: GlaxoSmithKline Intellectual Property Development Limited
- Applicants: Glaxosmithkline Intellectual Property Development Limited
- Inventors: Jae U. JEONG
- Web page: https://patentgrep.com/patent/US20200270273A1

## CPC

- C07D 513/04: Ortho-condensed systems
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compounds having Formula (I): wherein Q, X, A, L, B, Q4, R, RA, R5, n and m are as defined herein, and methods of making and using the same.

## Claims

### Claim 1

A compound according to Formula (I):
wherein:
X is O, S, SO, SO2, NH, CO, CH2, CF2, CH(CH3), CH(OH), or N(CH3);
Q is a 5-membered heteroaryl ring moiety, wherein the heteroaryl ring moiety contains one nitrogen, oxygen, or sulfur ring heteroatom, or contains one oxygen or sulfur ring heteroatom and 1, 2, or 3 nitrogen ring atoms or contains one nitrogen ring heteroatom and 2 or 3 additional nitrogen ring atoms;
Q4 is N or C;
n is 0-3;
each R is independently selected from halogen, cyano, (C1-C6)alkyl, halo(C1-C4)alkyl, (C1-C6)alkoxy, halo(C1-C4)alkoxy, hydroxyl, —COOH, (C1-C4)alkoxy(C1-C4)alkoxy-, (C1-C4)alkylSO2-, (C1-C4)alkylSO2NHC(O)—, (C1-C4)alkylC(O)NH—, ((C1-C4)alkyl)((C1-C4)alkyl)NC(O)—, (C1-C4)alkylC(O)—, (C1-C4)alkylOC(O)—, (C1-C4)alkylC(O)N(C1-C4)alkyl)-, (C1-C4)alkylNHC(O)—, (C1-C4)alkoxy(C2-C4)alkylNHC(O)—, (C1-C4)alkoxy(C2-C4)alkylC(O)NH—, (C1-C4)alkoxy(C2-C4)alkylNHC(O)NH—, (C1-C4)alkylSO2(C2-C4)alkylNHC(O)—, (C1-C4)alkylNHC(O)NH—, (C1-C4)alkylOC(O)NH—, hydroxy(C1-C4)alkylOC(O)NH—, and an optionally substituted 3-6 membered cycloalkyl, (C3-C6)cycloalkyl-C(O)—, phenyl, phenyl-C(O)—, 5-6 membered heterocycloalkyl-C(O)—, 5-6 membered heterocycloalkyl-(C1-C4)alkyl-NHC(O)—, 5-6 membered heterocycloalkyl-(C1-C4)alkoxy-, 5-6 membered heteroaryl, 5-6 membered heteroaryl-C(O)—, or 5-6 membered heteroaryl-C(O)NH— group,
wherein any of said optionally substituted 3-6 membered cycloalkyl, phenyl, 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl, including the optionally substituted cycloalkyl, phenyl, 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl moieties of the (C3-C6)cycloalkyl-C(O)—, phenyl-C(O)—, 5-6 membered heterocycloalkyl-C(O)—, 5-6 membered heterocycloalkyl-(C1-C4)alkyl-NHC(O)—, 5-6 membered heterocycloalkyl-(C1-C4)alkoxy-, 5-6 membered heteroaryl-C(O)—, or 5-6 membered heteroaryl-C(O)NH— groups, are optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, cyano, (C1-C6)alkyl, halo(C1-C4)alkyl, (C1-C6)alkoxy, halo(C1-C4)alkoxy, hydroxyl, —COOH, (C1-C4)alkoxy(C1-C4)alkoxy-, (C1-C4)alkylSO2-, (C1-C4)alkylSO2NHC(O)—, (C1-C4)alkylC(O)NH—, ((C1-C4)alkyl)((C1-C4)alkyl)NC(O)—, (C1-C4)alkylOC(O)—, (C1-C4)alkylC(O)N(C1-C4)alkyl)-, (C1-C4)alkylNHC(O)—, (C1-C4)alkoxy(C2-C4)alkylNHC(O)—, (C1-C4)alkoxy(C2-C4)alkylC(O)NH—, (C1-C4)alkoxy(C2-C4)alkylNHC(O)NH—, (C1-C4)alkylSO2(C2-C4)alkylNHC(O)—, (C1-C4)alkylNHC(O)NH—, (C1-C4)alkylOC(O)NH—, hydroxy(C1-C4)alkylOC(O)NH—, —NH2, —NH((C1-C4)alkyl), and —N((C1-C4)alkyl)((C1-C4)alkyl);
or two R groups, taken together with the atoms through which they are connected form an optionally substituted 5-7 membered carbocyclic or heterocyclic ring, wherein the optionally substituted 5-7 membered carbocyclic or heterocyclic ring is optionally substituted by 1-3 substituents each independently selected from the group consisting of halogen, cyano, (C1-C6)alkyl, halo(C1-C4)alkyl, (C1-C6)alkoxy, halo(C1-C4)alkoxy, hydroxyl, —COOH, (C1-C4)alkoxy(C1-C4)alkoxy-, (C1-C4)alkylSO2-, (C1-C4)alkylSO2NHC(O)—, (C1-C4)alkylC(O)NH—, ((C1-C4)alkyl)((C1-C4)alkyl)NC(O)—, (C1-C4)alkylOC(O)—, (C1-C4)alkylC(O)N(C1-C4)alkyl)-, (C1-C4)alkylNHC(O)—, (C1-C4)alkoxy(C2-C4)alkylNHC(O)—, (C1-C4)alkoxy(C2-C4)alkylC(O)NH—, (C1-C4)alkoxy(C2-C4)alkylNHC(O)NH—, (C1-C4)alkylSO2(C2-C4)alkylNHC(O)—, (C1-C4)alkylNHC(O)NH—, (C1-C4)alkylOC(O)NH—, hydroxy(C1-C4)alkylOC(O)NH—, —NH2, —NH((C1-C4)alkyl), and —N((C1-C4)alkyl)((C1-C4)alkyl), and the 5-6 heterocyclic ring contains one N or O atom;
R5 is H or methyl;
A is phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocycloalkyl, wherein the carbonyl moiety and L are substituted 1,3 on ring A;
m is 0 or m is 1 and RA is (C1-C4)alkyl; and
L is O, S, NH, N(CH3), CH2, CH2CH2, CH(CH3), CHF, CF2, CH2O, CH2N(CH3), CH2NH, or CH(OH);
B is an optionally substituted (C3-C6)cycloalkyl, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocycloalkyl, wherein said (C3-C6)cycloalkyl, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocycloalkyl is unsubstituted or is substituted by one or two substituents each independently selected from halogen, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, nitro, and (C1-C4)alkylC(O)—;
or the moiety -L-B is (C3-C6)alkyl, (C3-C6)alkoxy, halo(C3-C6)alkoxy, (C3-C6)alkenyl, or (C3-C6)alkenyloxy;
or a salt thereof.

### Claim 2 (depends on 1)

The compound or salt according to claim 1, wherein X is NH.

### Claim 3 (depends on 1)

The compound or salt according to claim 1, wherein X is S or CH2.

### Claim 4 (depends on 1)

The compound or salt according to claim 1, having Formula (II):
wherein:
Q1 is N, NRz, O, S, or CR1;
Q2 is N, NRz, O, S, or CR2;
Q3 is N, NRz, O, S, or CR3;
Q4 is N or C;
wherein at least one of Q1, Q2, Q3, and Q4 is N, NRz, O, or S;
each Rz is independently selected from H, (C1-C4)alkyl, —CO(C1-C6)alkyl, —CO—(C3-C6)cycloalkyl, optionally substituted phenyl, optionally substituted 5-6 membered heteroaryl, optionally substituted —CO-5-6 membered heterocycloalkyl, and optionally substituted —CO-5-6 membered heteroaryl, wherein said optionally substituted phenyl and optionally substituted 5-6 membered heteroaryl, including the optionally substituted 5-6 membered heteroaryl moiety of —CO-5-6 membered heteroaryl, is optionally substituted by 1-3 substituents each independently selected from halogen, cyano, (C1-C6)alkyl, halo(C1-C4)alkyl, (C1-C6)alkoxy, halo(C1-C4)alkoxy, hydroxyl, —COOH, (C1-C4)alkoxy(C1-C4)alkoxy, (C1-C4)alkylSO2-, (C1-C4)alkylSO2NHC(O)—, (C1-C4)alkylC(O)NH—, ((C1-C4)alkyl)((C1-C4)alkyl)NC(O)—, (C1-C4)alkylOC(O)—, (C1-C4)alkylC(O)N(C1-C4)alkyl)-, (C1-C4)alkylNHC(O)—, (C1-C4)alkoxy(C2-C4)alkylNHC(O)—, (C1-C4)alkoxy(C2-C4)alkylC(O)NH—, (C1-C4)alkoxy(C2-C4)alkylNHC(O)NH—, (C1-C4)alkylSO2(C2-C4)alkylNHC(O)—, (C1-C4)alkylNHC(O)NH—, (C1-C4)alkylOC(O)NH—, hydroxy(C1-C4)alkylOC(O)NH—, —NH2, —NH((C1-C4)alkyl), and —N((C1-C4)alkyl)((C1-C4)alkyl);
R1, R2 and R3 is independently selected from H, halogen, cyano, (C1-C6)alkyl, halo(C1-C4)alkyl, (C1-C6)alkoxy, halo(C1-C4)alkoxy, hydroxyl, —COOH, (C1-C4)alkoxy(C1-C4)alkoxy, (C1-C4)alkylSO2-, (C1-C4)alkylSO2NHC(O)—, (C1-C4)alkylC(O)NH—, ((C1-C4)alkyl)((C1-C4)alkyl)NC(O)—, (C1-C4)alkylOC(O)—, (C1-C4)alkylC(O)N(C1-C4)alkyl)-, (C1-C4)alkylNHC(O)—, (C1-C4)alkoxy(C2-C4)alkylNHC(O)—, (C1-C4)alkoxy(C2-C4)alkylC(O)NH—, (C1-C4)alkoxy(C2-C4)alkylNHC(O)NH—, (C1-C4)alkylSO2(C2-C4)alkylNHC(O)—, (C1-C4)alkylNHC(O)NH—, (C1-C4)alkylOC(O)NH—, hydroxy(C1-C4)alkylOC(O)NH—, 5-6 membered heterocycloalkyl-C(O)—, 5-6 membered heterocycloalkyl-(C1-C4)alkyl-NHC(O)—, 5-6 membered heterocycloalkyl-(C1-C4)alkoxy-, 3-6 membered cycloalkyl, 5-6 membered heteroaryl, or 5-6 membered heteroaryl-C(O)NH,
wherein said 3-6 membered cycloalkyl, 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl are optionally substituted by 1 or 2 substituents each independently selected from the group consisting of (C1-C4)alkyl and —(C1-C4)alkyl-CN;
or R2 and R3, or Rz and R3, or Rz and R2, taken together with the atoms through which they are connected form an optionally substituted 5-7 membered carbocyclic or heterocyclic ring, wherein the optionally substituted 5-7 membered carbocyclic or heterocyclic ring is optionally substituted by (C1-C6)alkyl or halo(C1-C4)alkyl, and the 5-6 heterocyclic ring contains one N or O atom.

### Claim 5 (depends on 1)

The compound or salt according to claim 1, wherein R5 is H.

### Claim 6 (depends on 1)

The compound or salt according to claim 1, wherein R5 is methyl.

### Claim 7 (depends on 1)

The compound or salt according to claim 1, according to Formula (III):
wherein:
A1 is C,
A4 is C or N,
and A2, A3, and A5 are each independently selected from CH, CRA, O, S, N, NH and NRA to form a furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl or tetrazolyl ring moiety,
wherein said ring moiety contains 0 or 1 of CRA and NRA.

### Claim 8 (depends on 7)

The compound or salt according to claim 7, wherein A1 is C, A4 is C or N, and A2, A3, and A5 are each independently selected from CH, O, N, and NH to form an oxazolyl, isoxazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl or tetrazolyl ring moiety.

### Claim 9 (depends on 7)

The compound or salt according to claim 7, wherein A1 and A4 are each C, and A2, A3 and A5 are each independently selected from N and NH to form a triazolyl ring moiety.

### Claim 10 (depends on 1)

The compound or salt according to claim 1 according to Formula (IV):
wherein s is 0 or 1, A10 is N.

### Claim 11 (depends on 1)

The compound or salt according to claim 1, according to Formula (V):
wherein:
A6, A7, A8, and A9 are each CH;
one of A6, A7, A8, and A9 is CRA and the others of A6, A7, A8, and A9 are CH;
one of A6, A7, A8, and A9 is N and the others of A6, A7, A8, and A9 are CH;
one of A6, A7, A8, and A9 is N—O and the other of A6, A7, A8, and A9 are CH.

### Claim 12 (depends on 1)

The compound or salt according to claim 1, wherein:
X is NH, S, or CH2;
Q1 is N, and Q2 is CR2, Q3 is S, and Q4 is C; or
Q1 is N, and Q2 is CR2, Q3 is O, and Q4 is C; or
Q1 is S, and Q2 is N, Q3 is CR3, and Q4 is C; or
Q1 is CR1, and Q2 is N, Q3 is O, and Q4 is C; or
Q1 is CR1, Q2 is CR2, Q3 is CR3, and Q4 is N;
each R1, R2 and R3 is H; or
one or two of any of R1, R2 and R3 is methyl and the remaining R1, R2 and R3 are H; or
R2 and R3, taken together with the atoms through which they are connected form an unsubstituted 6 membered aromatic ring or an unsubstituted non-aromatic ring;
A is triazolyl; and m is 0.

### Claim 13 (depends on 1)

The compound or salt according to claim 1, wherein L is O, S, N(CH3), CH2, CH2CH2, CH(CH3), CF2, CH2O, CH2N(CH3), or CH(OH).

### Claim 14 (depends on 1)

The compound or salt according to claim 1, wherein L is O, CH2, or NH.

### Claim 15 (depends on 1)

The compound or salt according to claim 1, wherein B is an optionally substituted pyrazolyl, thienyl, pyridinyl (pyridyl), oxo-pyridyl, pyrimidinyl, isoxazolyl, morpholinyl, or tetrahydrofuranyl, wherein the pyrazolyl, thienyl, pyridinyl, oxo-pyridyl, pyrimidinyl, isoxazolyl, morpholinyl, or tetrahydrofuranyl is optionally substituted by one or two independently selected (C1-C4)alkyl substituents.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The compound or salt according to claim 1, wherein B is unsubstituted phenyl.

### Claim 18 (depends on 1)

The compound or salt according to claim 1, wherein B is phenyl, substituted by 1 or 2 substituents independently selected from halogen, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, nitro, and (C1-C4)alkylC(O)—.

### Claim 19 (depends on 1)

The compound or salt according to claim 1, wherein B is phenyl, substituted by 1 or 2 substituents independently selected from halogen, (C1-C3)alkyl and (C1-C3)alkoxy.

### Claim 20 (depends on 1)

The compound or salt according to claim 1, wherein the compound is selected from the group consisting of:
5-benzyl-N-(6,8-dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-thieno[3,4-b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;
5-benzyl-N-(5-oxo-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-6-yl)-4H-1,2,4-triazole-3-carboxamide;
5-benzyl-N-(2-methyl-5-oxo-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-6-yl)-4H-1,2,4-triazole-3-carboxamide;
5-benzyl-N-(1-methyl-5-oxo-1,4,5,6,7,8-hexahydropyrrolo[3,2-b]azepin-6-yl)-4H-1,2,4-triazole-3-carboxamide;
5-benzyl-N-(1,3-dimethyl-5-oxo-1,4,5,6,7,8-hexahydropyrrolo[3,2-b]azepin-6-yl)-4H-1,2,4-triazole-3-carboxamide;
5-benzyl-N-(2-oxo-1,2,3,4,5,6-hexahydroazepino[3,2-b]indol-3-yl)-4H-1,2,4-triazole-3-carboxamide;
(S)-5-benzyl-N-(3,4-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-isothiazolo[4,5-b][1,4]diazepin-6-yl)-4H-1,2,4-triazole-3-carboxamide;
(R)-5-benzyl-N-(4-oxo-2,3,4,5-tetrahydropyrrolo[2,1-b][1,3,4]thiadiazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;
(R)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrrolo[2,1-b][1,3,4]thiadiazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; and
5-benzyl-N-(2-oxo-2,3,4,5,7,8,9,10-octahydro-1H-benzofuro[3,2-b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide;
or a tautomer thereof.

### Claim 21 (depends on 1)

The compound or salt according to claim 1, wherein the salt is a pharmaceutically acceptable salt.

### Claim at position 22

22-29. (canceled)
